# What the ELAD trial measured in the brains of people with Alzheimer’s disease

- Article ID: research-253
- Product: Liraglutide (liraglutide-702)
- Canonical page: https://heritagebiolabs.com/research-library/articles/253-what-the-elad-trial-measured-in-the-brains-of-people-with-alzheimers-disease
- Product collection: https://heritagebiolabs.com/research-library/products/liraglutide
- Product page: https://heritagebiolabs.com/product/liraglutide-702
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids linked by peptide bonds. Some can change cell activity by activating a receptor. Liraglutide is a peptide that activates the GLP-1 receptor and is approved for specific uses in diabetes and weight management, depending on the product. The ELAD trial studied it in people with mild to moderate Alzheimer’s disease, an investigated use. The researchers focused on whether they could detect a change in how the brain used glucose. [1, 2, 3]

The phase 2b trial randomized 204 adults without diabetes to liraglutide or placebo for 52 weeks. It used a type of PET scan that tracks a glucose-like tracer to estimate glucose metabolism in the brain. The study also included assessments of memory, executive function and ability to carry out everyday activities. Those measures help distinguish an imaging result from changes a participant or caregiver might observe. [1]

The investigators did not find a statistically significant difference in the primary measure of brain glucose metabolism. They reported a difference favoring liraglutide on a secondary executive function measure, with an unadjusted statistical test. They did not find significant differences on the reported everyday activities or overall dementia rating measures. The pattern is more informative when read outcome by outcome than if the paper is reduced to whether one test favored the drug. [1]

A phase 2 study can help determine which measures to carry into a larger study. When multiple secondary measures are considered, an individual result can be more uncertain than the main comparison. The secondary cognitive finding gives researchers a specific result to investigate again. The primary imaging test and the other measures provide context for how much was established in this trial. [1]

ELAD’s findings apply to a defined group of adults with mild to moderate disease and a one-year follow-up. They do not expand the FDA-approved indications. The trial is an example of researchers testing a plausible pathway in people and finding that the main measured response was uncertain despite an interesting result on one secondary measure. [1, 2, 3]

## Sources

1. Paul Edison et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nature Medicine (publication 2025-12-01). <https://pubmed.ncbi.nlm.nih.gov/41326666/>
2. U.S. Food and Drug Administration. VICTOZA (liraglutide) injection, prescribing information. Drugs@FDA (publication 2025-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf>
3. U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information. Drugs@FDA (publication 2025-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s022lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 051 - Liraglutide and MGF.docx; article 253; content SHA-256 8177ed3eaa982eda9ff26ef0d7e52b04d96018fa765f67a3bf743406df1f54f0.
